Cited 1 times in
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.contributor.author | 임선민 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 홍민희 | - |
dc.date.accessioned | 2023-04-07T01:32:29Z | - |
dc.date.available | 2023-04-07T01:32:29Z | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 1758-8340 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/193976 | - |
dc.description.abstract | Background: The clinical utility of plasma tumor mutational burden (pTMB) requires further validation. Herein, the pTMB and genetic alterations were investigated as predictive biomarkers for anti-PD-1 monotherapy outcome in metastatic non-small cell lung cancer (NSCLC). Methods: The GuardantOMNI panel (Guardant Health) was used to identify pTMB and genetic alterations. Data from 99 patients with metastatic NSCLC treated with pembrolizumab or nivolumab in first-, second-, or third-line settings between June 2016 and December 2020 were collected. Associations between pTMB and clinical benefit rate (CBR, stable disease ⩾6 months or partial response), progression-free survival (PFS), and overall survival (OS) were assessed. Results: Median pTMB in 84 patients was 10.8 mutations/megabase (mut/Mb). Histological analyses revealed that 61 and 36% of the patients had adenocarcinomas and squamous NSCLC, respectively. Most patients were treated with nivolumab (74%) and most anti-PD-1 agents were administered as second-line treatment (70%). The median follow-up duration was of 10.9 months (range, 0.2-40.7). Patients with high pTMB (⩾19 mut/Mb) had a higher CBR (69%) compared with low pTMB patients (33%; p = 0.01). ARID1A (p = 0.007) and either ERBB2 or KIT mutations (p = 0.012) were positive and negative determinants, respectively, for clinical benefit. Multivariate analysis further showed that high pTMB was an independent predictive biomarker for both PFS [hazard ratio (HR) = 0.44, 95% confidence interval (CI): 0.22-0.88, p = 0.02] and OS (HR = 0.37, 95% CI: 0.18-0.76, p = 0.007). Conclusion: High pTMB (⩾19 mut/Mb) is significantly associated with CBR in patients with NSCLC treated with anti-PD-1 agents. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Sage | - |
dc.relation.isPartOf | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jii Bum Lee | - |
dc.contributor.googleauthor | Hyung Soon Park | - |
dc.contributor.googleauthor | Su Jin Choi | - |
dc.contributor.googleauthor | Seong Gu Heo | - |
dc.contributor.googleauthor | Ho Jung An | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Sun Min Lim | - |
dc.contributor.googleauthor | Kyle Chang | - |
dc.contributor.googleauthor | Katie Quinn | - |
dc.contributor.googleauthor | Justin Odegaard | - |
dc.contributor.googleauthor | Byoung Yong Shim | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.identifier.doi | 10.1177/17588359221141761 | - |
dc.contributor.localId | A01166 | - |
dc.contributor.localId | A03369 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04393 | - |
dc.relation.journalcode | J02720 | - |
dc.identifier.eissn | 1758-8359 | - |
dc.identifier.pmid | 36544541 | - |
dc.subject.keyword | anti-PD-1 | - |
dc.subject.keyword | clinical benefit | - |
dc.subject.keyword | genetic alterations | - |
dc.subject.keyword | non-small cell lung cancer | - |
dc.subject.keyword | plasma tumor mutational burden | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.contributor.affiliatedAuthor | 임선민 | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.contributor.affiliatedAuthor | 홍민희 | - |
dc.citation.volume | 14 | - |
dc.citation.startPage | 17588359221141761 | - |
dc.identifier.bibliographicCitation | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, Vol.14 : 17588359221141761, 2022-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.